Raymond L. M. Wong
Hong Kong Eye Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Raymond L. M. Wong.
Retina-the Journal of Retinal and Vitreous Diseases | 2013
Ian Y. Wong; Raymond L. M. Wong; Paul Zhao; Wico W. Lai
Purpose: To investigate the relationship of hypercholesterolemia and choroidal thickness in normal healthy volunteers. Method: This was a cross-sectional observational study. Volunteers with no ocular abnormalities were examined using enhanced depth imaging optical coherence tomography. Choroidal and retinal thicknesses were measured at the fovea, and at 4 different locations 1 mm superior, inferior, temporal, and nasal to the fovea. Subjects were further divided into those with hypercholesterolemia (Group 1) and normal control subjects (Group 2) for subgroup analysis regarding the effect of hypercholesterolemia on choroidal thickness. Subjects with hypertension and diabetes were excluded. Results: A total of 322 eyes of 161 subjects were studied. Mean age was 59.9 years (range, 24–84 years). The mean subfoveal choroidal thickness was 261 ± 98.7 &mgr;m. Mean subfoveal choroidal thickness negatively correlated with age (r = −0.326; P = 0.001). The mean serum total cholesterol was 5.02 ± 0.98 mmol/L. In Group 1, it was 5.65 ± 1.15 mmol/L, while in Group 2, it was 4.72 ± 0.73 mmol/L. The difference was statistically significant (P = 0.003). Subjects in Group 1 tended to be older and have worse vision, although the difference did not reach statistical significance. The mean subfoveal choroidal thickness in Group 1 was 306 ± 111 &mgr;m, while that in Group 2 was 258 ± 97 &mgr;m. The difference was statistically significant (P = 0.041). The same difference was also found at the 1 mm nasal (P = 0.041) and 1 mm superior (P = 0.040). Conclusion: The subfoveal choroidal thickness was found to be significantly higher in subjects with hypercholesterolemia. This has to be taken into account when analyzing choroidal thickness.
Clinical and Experimental Ophthalmology | 2011
Timothy Yy Lai; Raymond L. M. Wong; Fiona O. J. Luk; Vanissa Ws Chow; Carmen K. M. Chan; Dennis S.C. Lam
Background: To evaluate the ophthalmic manifestations and risk factors for mortality in HIV patients in the post‐highly active anti‐retrovirus therapy (HAART) era.
Diabetic Medicine | 2009
Juliana C.N. Chan; W. Y. So; G. T. C. Ko; P. C. Y. Tong; Xilin Yang; Ronald C.W. Ma; A. P. S. Kong; Raymond L. M. Wong; F. Le Coguiec; B. Tamesis; Troels Wolthers; Greg Lyubomirsky; P. Chow
Aims The Joint Asia Diabetes Evaluation (JADE) Program is the first web‐based program incorporating a comprehensive risk engine, care protocols, clinical decision and self‐management support to improve ambulatory diabetes care. The aim was to validate the risk stratification system of the JADE Program using a large prospective cohort.
Journal of Ophthalmology | 2012
Raymond L. M. Wong; Rita Gangwani; Lester W. H. Yu; Jimmy S. M. Lai
Purpose. To review the newer treatments for bacterial keratitis. Data Sources. PubMed literature search up to April 2012. Study Selection. Key words used for literature search: “infectious keratitis”, “microbial keratitis”, “infective keratitis”, “new treatments for infectious keratitis”, “fourth generation fluoroquinolones”, “moxifloxacin”, “gatifloxacin”, “collagen cross-linking”, and “photodynamic therapy”. Data Extraction. Over 2400 articles were retrieved. Large scale studies or publications at more recent dates were selected. Data Synthesis. Broad spectrum antibiotics have been the main stay of treatment for bacterial keratitis but with the emergence of bacterial resistance; there is a need for newer antimicrobial agents and treatment methods. Fourth-generation fluoroquinolones and corneal collagen cross-linking are amongst the new treatments. In vitro studies and prospective clinical trials have shown that fourth-generation fluoroquinolones are better than the older generation fluoroquinolones and are as potent as combined fortified antibiotics against common pathogens that cause bacterial keratitis. Collagen cross-linking was shown to improve healing of infectious corneal ulcer in treatment-resistant cases or as an adjunct to antibiotics treatment. Conclusion. Fourth-generation fluoroquinolones are good alternatives to standard treatment of bacterial keratitis using combined fortified topical antibiotics. Collagen cross-linking may be considered in treatment-resistant infectious keratitis or as an adjunct to antibiotics therapy.
Retina-the Journal of Retinal and Vitreous Diseases | 2010
Raymond L. M. Wong; Ping Hou; Kwong Wai Choy; Sylvia W. Y. Chiang; Pancy O. S. Tam; Wai-Man Chan; Dennis S.C. Lam; Chi Pui Pang; Timothy Y. Y. Lai
Purpose: The purpose of this study was to investigate the BEST1 gene mutations in Chinese patients with Best vitelliform macular dystrophy (BVMD). Methods: Twenty-six subjects from 7 Chinese families with BVMD and 100 unrelated healthy Chinese subjects without a family history of BVMD were screened for mutations in the BEST1 gene by direct sequencing. The subjects underwent complete ophthalmologic examination and BEST1 gene screening. Results: Six novel missense mutations (Thr2Asn, Leu75Phe, Ser144Asn, Arg255Trp, Pro297Thr, and Asp301Gly) and 1 previously reported mutation (Arg218Cys) were identified. Each family was found to have a unique BEST1 mutation that segregated with the disease. Two of the six novel mutations are located within the four previously reported common mutation clusters within the BEST1 gene. One family with patients having homozygous Leu75Phe mutations did not have the more severe BVMD phenotype. None of the patients with mutations was identified among the 100 healthy control subjects. Conclusion: A large number of unique novel missense mutations was found in Chinese patients with BVMD, suggesting considerable interethnic differences between the mutation sites in the BEST1 gene in different populations. The few truncating BEST1 mutations and the lack of a more severe phenotype in homozygous patients suggest that the missense BEST1 mutation may produce a dominant negative effect on wild-type BEST1 gene.
Clinical Ophthalmology | 2014
Jacky W. Y. Lee; Catherine C.L. Liu; Jonathan C.H. Chan; Raymond L. M. Wong; Ian Ian Y Wong; Jimmy S. M. Lai
Purpose To determine the predictors of success for adjuvant selective laser trabeculoplasty (SLT) in Chinese primary open angle glaucoma (POAG) patients. Methods This prospective study recruited Chinese subjects with unilateral or bilateral POAG currently taking medication to reduce intraocular pressure (IOP). All subjects received a single session of 360° SLT treatment and continued their medications for 1 month. SLT success was defined as IOP reduction ≥20% at 1 month. The following covariates were analyzed in both groups via univariate and multivariate analyses: age, sex, lens status, initial IOPs, post-SLT IOPs, number and type of medications, SLT shots and energy, and pre-SLT investigations. Results In 51 eyes of 33 POAG subjects, the success rate of SLT was 47.1%. Certain groups of patients were associated with greater success using univariate analysis. These groups included the following: older age (coefficient =0.1; OR: 1.1; P=0.0003), a higher pre-SLT IOP (coefficient =0.3; OR: 1.3; P=0.0005), using four types of antiglaucoma medication (coefficient =2.1; OR: 8.4; P=0.005), a greater degree of spherical equivalent (coefficient =2.1; OR: 8.4; P=0.005), and the use of a topical carbonic anhydrase inhibitor (coefficient =1.7; OR: 6.0; P=0.003). None of the covariates were significant using multivariate analysis. Conclusion Older age, a higher pretreatment IOP, using multiple antiglaucoma medications especially topical carbonic anhydrase inhibitor, and higher refractive errors were associated with greater SLT success.
Acta Ophthalmologica | 2015
Tommy C. Y. Chan; Tiffany Lau; Jacky W. Y. Lee; Ian Y. Wong; Vishal Jhanji; Raymond L. M. Wong
Collagen cross‐linking (CXL) with ultraviolet light‐activated riboflavin is a corneal surface procedure developed for the treatment of keratoconus and corneal ectasia. With the known microbicidal and corneal stiffening effects of ultraviolet irradiation and photoactivated riboflavin, it has recently been introduced for the management of infectious keratitis, especially for ulcers resistant to antimicrobial therapy or associated with corneal melting. Various authors have attempted to use CXL as an adjunctive, salvage or even as the sole treatment for infectious corneal ulcers. The aim of this review was to provide a summary of the clinical studies in the literature. It is worth noting that there is still no consensus on the treatment protocol of CXL against infectious keratitis. The disparities in outcome measures, treatment protocol and study design can confound the interpretation and hamper the generalization of the study results. Based on current evidence, the role of CXL in infectious keratitis remained unclear despite the reported success in some clinical cases. Further investigations are warranted concerning the efficacy and safety of treating infectious keratitis with CXL.
Journal of Glaucoma | 2016
Jacky W. Y. Lee; Mandy Oi Man Wong; Raymond L. M. Wong; Jimmy S. M. Lai
Purpose:To investigate the correlation of intraocular pressure (IOP)-lowering effects of selective laser trabeculoplasty (SLT) between the 2 eyes treated with SLT in open-angle glaucoma (OAG). Methods:This prospective cohort study sequentially recruited subjects with bilateral OAG. All subjects received a single session of 360-degree SLT treatment. Success was defined as IOP reduction of ≥20%. Spearman correlation was used to compare the following parameters between the 2 eyes following SLT: IOP at day 1, 1 week, and 1 month; percentage of success; and IOP reduction. Results:In 84 eyes of 42 subjects that received bilateral SLT treatment, both eyes had statistically comparable baseline characteristics. There were significant correlations between the IOP in both eyes at all time intervals following SLT as well as for the percentage of IOP reduction and the success rate at 1 month after SLT (all r≥0.7, P<0.0001). A total of 42.9% of subjects had bilateral success and 38.1% had bilateral nonsuccess with a significant correlation between both eyes in these 2 groups (Spearman r>0.6, P<0.02). Nineteen percent had success in 1 eye and nonsuccess in the fellow eye with an inverse correlation between the 2 eyes (Spearman r=−0.7, P=0.03). Conclusion:There is a strong and significant correlation in the IOP-lowering response to SLT between both eyes in near 80% of treated OAG subjects, whereas near 20% had an asymmetrical and inverse response to SLT between both the eyes.
British Journal of Ophthalmology | 2015
Lawrence P. Iu; Paul Zhao; Ian Y. Yeung; Nicholas S. Fung; Jacky Wyj Lee; Raymond L. M. Wong; Victor Chong; Ian Y. Wong
Purpose To evaluate the efficacy and safety of sequential therapy with ranibizumab followed by dexamethasone intravitreal implant compared with dexamethasone monotherapy for macular oedema (MO) secondary to retinal vein occlusion (RVO). Methods In this retrospective interventional study, the medical records of subjects with MO due to RVO who received either ranibizumab followed by dexamethasone intravitreal implant (Group 1) or dexamethasone-implant monotherapy (Group 2) were included. Primary outcome was the proportion of subjects who exhibited best-corrected visual acuity (VA) gain and resolution of MO within 6 months. Results Thirty-three eyes were included (17 in Group 1, 16 in Group 2). More subjects in Group 1 exhibited a VA gain of at least 0.5 (LogMAR units hereafter) than Group 2 (29% vs 0%, p=0.044). The speed of VA gain was greater in Group 1 (1.4±0.8 months vs 2.7±1.4 months, p=0.020). MO was controlled in more subjects in Group 1 at all measured time intervals, and this difference was statistically significant at 3 months and 4 months. Subjects with branch RVO experienced VA gain more rapidly if they were from Group 1 (p=0.023). Conclusions Sequential therapy was found to be more effective than dexamethasone monotherapy in treating MO due to RVO.
Indian Journal of Ophthalmology | 2015
Tiffany Lau; Ian Y. Wong; Lawrence P. Iu; Jay Chhablani; Tao Yong; Koizumi Hideki; Jacky W. Y. Lee; Raymond L. M. Wong
Optical coherence tomography (OCT) is a noninvasive imaging modality providing high-resolution images of the central retina that has completely transformed the field of ophthalmology. While traditional OCT has produced longitudinal cross-sectional images, advancements in data processing have led to the development of en-face OCT, which produces transverse images of retinal and choroidal layers at any specified depth. This offers additional benefit on top of longitudinal cross-sections because it provides an extensive overview of pathological structures in a single image. The aim of this review was to discuss the utility of en-face OCT in the diagnosis and management of age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV). En-face imaging of the inner segment/outer segment junction of retinal photoreceptors has been shown to be a useful indicator of visual acuity and a predictor of the extent of progression of geographic atrophy. En-face OCT has also enabled high-resolution analysis and quantification of pathological structures such as reticular pseudodrusen (RPD) and choroidal neovascularization, which have the potential to become useful markers for disease monitoring. En-face Doppler OCT enables subtle changes in the choroidal vasculature to be detected in eyes with RPD and AMD, which has significantly advanced our understanding of their pathogenesis. En-face Doppler OCT has also been shown to be useful for detecting the polypoid lesions and branching vascular networks diagnostic of PCV. It may therefore serve as a noninvasive alternative to fluorescein and indocyanine green angiography for the diagnosis of PCV and other forms of the exudative macular disease.